Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1990-05-31
1993-08-17
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514410, 540145, A61K 31555, A61K 3140
Patent
active
052369153
ABSTRACT:
A chelated compound of the formula: ##STR1## where R.sub.1 is independently at each occurrence, ##STR2## R.sub.2 is independently at each occurrence hydrogen, lower alkyl, lower alkyl ester, lower alkyl ether, hydroxy or halogen; A is H, Li, Na, Ca+, Mg+or Zn+; and Mn is trivalent manganese; provided that, at least two and no more than three R.sub.1 radicals are ##STR3## The compound of the invention is particularly suitable for use in a physiologically compatible composition comprising a physiologically compatible liquid carrier for magnetic resonance imaging. The compound is also suitable as a chelate for removal of manganese from a system.
The invention also comprises a method for enhanced magnetic imaging of a mammal organism which comprises introducing the composition at a level of from 20 to 200 mg/Kg of body weight into the circulatory system of the organism; and making a magnetic resonance image of at least a portion of said organism at from 30 minutes to 36 hours after said introduction.
REFERENCES:
patent: 5010073 (1991-04-01), Kappas et al.
Okura, et al Chemical Abstracts vol. 97, 1982, Abstract 41391z.
"Paramagnetic Metalloporphyrins as Potential Contrast Agents in NMR Imaging", Chen et al., Mar. 1984, FEBS Letters, pp. 70-74.
"Metalloporphyrin Contrast Agents for Magnetic Resonance Imaging of Human Tumors in Mice", Patronas et al., Mar. 1986, Cancer Treatment Reports, vol. 70, No. 3, pp. 391-395.
"Proton Relaxation Enhancement by Manganese (III) TPPS.sub.4 in a Model Tumor System", Fiel et al., 1987, Magnetic Resonance Imaging, pp. 149-156.
"Metalloporphyrin Contrast Enhancement of Tumors in Magnetic Resonance Imaging", Ogan et al., Oct. 1987, Investigative Radiology, vol. 22, ppp. 822-828.
"Metalloporphyrin Enhancement of Magnetic Resonance Imaging of Human Tumor Xenografts in Nude Mice", Furmanski et al., Aug. 15, 1988, Cancer Research, pp. 4604-4610.
"Mechanism of the Localization of Manganese (III) Mesotetra (4-Sulfonatophenyl) Porphine in Mice Bearing L1210 Tumors", Fiel et al., 1988, Cancer Letters, pp. 23-32.
"Isointense Model for the Evaluation of Tumor-Specific MRI Contrast Agents", Button et al., 1988, Magnetic Resonance Imaging, vol. 6, pp. 275-280.
Megnin et al., Biochim. et Biophys. Acta 929: 173-181 (1987).
Fiel R. J., Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, vol. 6, Issue No. 6 (1989).
Henkelman R. M. et al., Magnetic Resonance in Medicine 4, 61-66 (1987).
Bloom Mark G.
Daus Donald G.
Dunn Michael L.
Health Research , Inc.
Mudd James F.
LandOfFree
Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing ag does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing ag, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing ag will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2243820